Prime Medicine (PRME) Amortization of Deferred Charges (2021 - 2026)

Prime Medicine's Amortization of Deferred Charges history runs 6 years deep, the most recent figure standing at $2.8 million for Q1 2026.

• Quarterly Amortization of Deferred Charges rose 17.82% year-over-year to $2.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $10.1 million (down 11.31% YoY) and the FY2025 annual result came in at $9.7 million, down 21.51% from the prior year.
• Amortization of Deferred Charges was $2.8 million for Q1 2026 at Prime Medicine, up from $2.6 million in the prior quarter.
• Across five years, Amortization of Deferred Charges topped out at $4.6 million in Q2 2024 and bottomed at $1.8 million in Q1 2022.
• A 5-year average of $2.8 million and a median of $2.8 million in 2022 frame the typical range for Amortization of Deferred Charges.
• Annual changes were most pronounced in 2022 — Amortization of Deferred Charges soared 102.31% — and 2025, when it tumbled 48.61%.
• Prime Medicine's Amortization of Deferred Charges stood at $2.8 million in 2022, then climbed by 19.66% to $3.3 million in 2023, then slumped by 34.05% to $2.2 million in 2024, then climbed by 17.89% to $2.6 million in 2025, then advanced by 9.22% to $2.8 million in 2026.
• Business Quant data shows PRME's Amortization of Deferred Charges at $2.8 million in Q1 2026, $2.6 million in Q4 2025, and $2.3 million in Q3 2025.